Sponsors (12)
The bill increases national security and biosafety by expanding export controls and licensing for synthetic genetic sequences, but does so at the cost of added compliance burdens, potential overblocking of benign research, and slower international scientific collaboration and commercialization.
U.S. national security and the general public: tighter export controls and licensing reduce the risk that synthetic DNA/RNA and digital genetic-sequence data are acquired by foreign adversaries and used to modernize hostile military or intelligence capabilities.
Public health and biosafety stakeholders: limiting transfers of digital genetic-sequence data to jurisdictions of concern lowers the chance that data are misused (for example, to design or optimize pathogens) abroad.
U.S. biotech companies, researchers, and innovators: export controls help protect intellectual property and sensitive research from theft or diversion to competitors or adversaries.
Researchers, startups, cloud providers, and small biotech firms: new licensing and export-control requirements will impose compliance costs, administrative burdens, and delays that can slow research, commercialization, and competitiveness.
Scientists, public-health researchers, and patients: broadly written or poorly targeted controls risk hindering legitimate international scientific collaboration and public-health research (including work on diagnostics, vaccines, and treatments).
Academic institutions and industry partners: restrictions on transfers to flagged countries will curb collaboration with foreign academics and companies in jurisdictions of concern, potentially slowing scientific progress and partnerships.
Based on analysis of 3 sections of legislative text.
Requires Commerce to require licenses for exporting or transferring digital sequence files of human- or AI‑designed synthetic DNA/RNA to foreign entities of concern, with limited exclusions.
Introduced December 11, 2025 by Warren Davidson · Last progress December 11, 2025
Requires the Commerce Department to create a licensing requirement, within one year, for exporting, reexporting, or transferring in-country any digital file that encodes human- or AI-designed synthetic DNA or RNA to any “foreign entity of concern.” It defines covered terms (digital sequence, synthetic DNA/RNA, foreign entity/country of concern) and carves out information already excluded under existing export-control rules. Also states Congress’s view that the People’s Republic of China uses legal and policy tools to compel civilian organizations to support military and intelligence goals and that unrestricted export of sequence data risks revealing biological designs and enabling intellectual property theft and military or human-rights harms.